{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:45:40Z","timestamp":1791398740551,"version":"4.3.3"},"reference-count":31,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,1,5]]},"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      The use of magnesium sulfate (MgSO\n                      <jats:sub>4<\/jats:sub>\n                      ) in European obstetric units is unknown. We aimed to describe reported policies and actual use of MgSO\n                      <jats:sub>4<\/jats:sub>\n                      in women delivering before 32\u2005weeks of gestation by indication.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from the European Perinatal Intensive Care in Europe (EPICE) population-based cohort study of births before 32\u2005weeks of gestation in 19 regions in 11 European countries. Data were collected from April 2011 to September 2012 from medical records and questionnaires. The study population comprised 720 women with severe pre-eclampsia, eclampsia or HELLP and 3658 without pre-eclampsia delivering from 24 to 31\u2005weeks of gestation in 119 maternity units with 20 or more very preterm deliveries per year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among women with severe pre-eclampsia, eclampsia or HELLP, 255 (35.4%) received MgSO\n                      <jats:sub>4<\/jats:sub>\n                      before delivery. 41% of units reported use of MgSO\n                      <jats:sub>4<\/jats:sub>\n                      whenever possible for pre-eclampsia and administered MgSO\n                      <jats:sub>4<\/jats:sub>\n                      more often than units reporting use sometimes. In women without pre-eclampsia, 95 (2.6%) received MgSO\n                      <jats:sub>4<\/jats:sub>\n                      . 9 units (7.6%) reported using MgSO\n                      <jats:sub>4<\/jats:sub>\n                      for fetal neuroprotection whenever possible. In these units, the median rate of MgSO\n                      <jats:sub>4<\/jats:sub>\n                      use for deliveries without severe pre-eclampsia, eclampsia and HELLP was 14.3%. Only 1\u2005unit reported using MgSO\n                      <jats:sub>4<\/jats:sub>\n                      as a first-line tocolytic. Among women without pre-eclampsia, MgSO\n                      <jats:sub>4<\/jats:sub>\n                      use was not higher in women hospitalised before delivery for preterm labour.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Severe pre-eclampsia, eclampsia or HELLP are not treated with MgSO\n                      <jats:sub>4<\/jats:sub>\n                      as frequently as evidence-based medicine recommends. MgSO\n                      <jats:sub>4<\/jats:sub>\n                      is seldom used for fetal neuroprotection, and is no longer used for tocolysis. To continuously lower morbidity, greater attention to use of MgSO\n                      <jats:sub>4<\/jats:sub>\n                      is needed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-013952","type":"journal-article","created":{"date-parts":[[2017,1,28]],"date-time":"2017-01-28T20:10:31Z","timestamp":1485634231000},"page":"e013952","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Use of magnesium sulfate before 32\u2005weeks of gestation: a European population-based cohort study"],"prefix":"10.1136","volume":"7","author":[{"given":"H T","family":"Wolf","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Huusom","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Piedvache","sequence":"additional","affiliation":[{"name":"Inserm UMR 1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epop\u00e9), Center for Epidemiology and Statistics Sorbonne Paris Cit\u00e9, DHU Risks in pregnancy, Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, University Hospital, Philipps University, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Norman","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Intervention and Technology, Division of Pediatrics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Neonatal Medicine, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zeitlin","sequence":"additional","affiliation":[{"name":"Inserm UMR 1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epop\u00e9), Center for Epidemiology and Statistics Sorbonne Paris Cit\u00e9, DHU Risks in pregnancy, Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,1,27]]},"reference":[{"key":"2025121223081533000_7.1.e013952.1","doi-asserted-by":"crossref","unstructured":"Duley L , G\u00fclmezoglu AM , Henderson-Smart DJ , et al . Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010;(11):CD000025. doi:10.1002\/14651858.CD000025.pub2","DOI":"10.1002\/14651858.CD000025.pub2"},{"key":"2025121223081533000_7.1.e013952.2","doi-asserted-by":"crossref","unstructured":"Crowther CA , Brown J , McKinlay CJD , et al . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2014;(8):CD001060. doi:10.1002\/14651858.CD001060.pub2","DOI":"10.1002\/14651858.CD001060.pub2"},{"key":"2025121223081533000_7.1.e013952.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.04.005"},{"key":"2025121223081533000_7.1.e013952.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.04.003"},{"key":"2025121223081533000_7.1.e013952.5","doi-asserted-by":"crossref","unstructured":"Doyle LW , Crowther CA , Middleton P , et al . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009;(1):CD004661. doi:10.1002\/14651858.CD004661.pub3","DOI":"10.1002\/14651858.CD004661.pub3"},{"key":"2025121223081533000_7.1.e013952.6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/01443615.2011.638999","article-title":"Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies","volume":"32","author":"Wolf","year":"2012","journal-title":"J Obstet Gynaecol"},{"key":"2025121223081533000_7.1.e013952.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1471-0528.2010.02782.x","article-title":"Antenatal magnesium sulphate may prevent cerebral palsy in preterm infants-but are we convinced? Evaluation of an apparently conclusive meta-analysis with trial sequential analysis","volume":"118","author":"Huusom","year":"2011","journal-title":"BJOG"},{"key":"2025121223081533000_7.1.e013952.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101765"},{"key":"2025121223081533000_7.1.e013952.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2012.01.013"},{"key":"2025121223081533000_7.1.e013952.10","doi-asserted-by":"publisher","DOI":"10.1113\/JP270614"},{"key":"2025121223081533000_7.1.e013952.11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1447-0756.2011.01806.x","article-title":"Randomized controlled study comparing effect of magnesium sulfate with placebo on fetal umbilical artery and middle cerebral artery blood flow in mild preeclampsia at \u2265 34 weeks gestational age","volume":"38","author":"Dasgupta","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"key":"2025121223081533000_7.1.e013952.12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113715"},{"key":"2025121223081533000_7.1.e013952.13","unstructured":"WHO recommendations for Prevention and treatment of pre-eclampsia and eclampsia. http:\/\/apps.who.int\/iris\/bitstream\/10665\/44703\/1\/9789241548335_eng.pdf. (Retrieved 25 April 2016)."},{"key":"2025121223081533000_7.1.e013952.14","unstructured":"National Institute for Health and Care Excellence (NICE). Preterm labour and birth. http:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0080792\/pdf\/PubMedHealth_PMH0080792.pdf (Retrieved 25 April 2016)."},{"key":"2025121223081533000_7.1.e013952.15","unstructured":"Clinical practice guideline. Antenatal magnesium sulphate for fetal neuroprotection. http:\/\/www.hse.ie\/eng\/about\/Who\/clinical\/natclinprog\/obsandgynaeprogramme\/mgso.pdf (Retrieved 25 April 2016)."},{"key":"2025121223081533000_7.1.e013952.16","unstructured":"Prevention of preterm birth in women at risk: selected topics [Internet]. (cited 3 August 2016). https:\/\/kce.fgov.be\/sites\/default\/files\/page_documents\/KCE_228Cs_Preterm birth_Synthesis.pdf (Retrieved 25 April 2016)."},{"key":"2025121223081533000_7.1.e013952.17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1701-2163(16)30047-0","article-title":"Magnesium sulphate for eclampsia and fetal neuroprotection: a comparative analysis of protocols across Canadian tertiary perinatal centres","volume":"37","author":"De Silva","year":"2015","journal-title":"J Obstet Gynaecol Can"},{"key":"2025121223081533000_7.1.e013952.18","doi-asserted-by":"crossref","first-page":"14732","DOI":"10.1038\/srep14732","article-title":"Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants","volume":"5","author":"Bouet","year":"2015","journal-title":"Sci Rep"},{"key":"2025121223081533000_7.1.e013952.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2976"},{"key":"2025121223081533000_7.1.e013952.20","unstructured":"Hypertension in pregnancy: diagnosis and management (NICE guidelines) [Internet]. (cited 4 August 2016). https:\/\/www.nice.org.uk\/guidance\/cg107\/chapter\/1-Guidance"},{"key":"2025121223081533000_7.1.e013952.21","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/1471-0528.12712","article-title":"Eclampsia, a comparison within the International Network of Obstetric Survey Systems","volume":"121","author":"Schaap","year":"2014","journal-title":"BJOG"},{"key":"2025121223081533000_7.1.e013952.22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/aogs.12882","article-title":"Eclampsia in Finland; 2006 to 2010","volume":"95","author":"Jaatinen","year":"2016","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2025121223081533000_7.1.e013952.23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.annfar.2012.09.004","article-title":"[Magnesium sulfate in the prophylaxis of eclampsia: a retrospective study]","volume":"31","author":"Bourret","year":"2012","journal-title":"Ann Fr Anesth Reanim"},{"key":"2025121223081533000_7.1.e013952.24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2471\/BLT.06.037911","article-title":"Magnesium sulfate is not used for pre-eclampsia and eclampsia in Mexico and Thailand as much as it should be","volume":"85","author":"Lumbiganon","year":"2007","journal-title":"Bull World Health Organ"},{"key":"2025121223081533000_7.1.e013952.25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059158"},{"key":"2025121223081533000_7.1.e013952.26","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-10-340"},{"key":"2025121223081533000_7.1.e013952.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7519.765"},{"key":"2025121223081533000_7.1.e013952.28","unstructured":"Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection. Committee opinion. March 2010. (ACOG) [Internet]. (cited 9 August 2016). http:\/\/www.acog.org\/Resources-And-Publications\/Committee-Opinions\/Committee-on-Obstetric-Practice\/Magnesium-Sulfate-Before-Anticipated-Preterm-Birth-for-Neuroprotection"},{"key":"2025121223081533000_7.1.e013952.29","unstructured":"Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth. Scientific Impact Paper No. 29. August 2011. (RCOG) [Internet]. (cited 3 August 2016). https:\/\/www.rcog.org.uk\/globalassets\/documents\/guidelines\/scientific-impact-papers\/sip_29.pdf"},{"key":"2025121223081533000_7.1.e013952.30","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181ae98c2"},{"key":"2025121223081533000_7.1.e013952.31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3934\/publichealth.2015.4.727","article-title":"Does antenatal administration of magnesium sulphate prevent cerebral palsy and mortality in preterm infants? A study protocol","volume":"2","author":"Wolf","year":"2015","journal-title":"AIMS Public Heal"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-013952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:08:25Z","timestamp":1765609705000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-013952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,27]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1136\/bmjopen-2016-013952"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-013952","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}